Morningstar (MORN) Surges Amid Market Optimism
During the trading session that closed at 09:30 AM Central Europe on Thursday, 22 November 2026, Morningstar Inc. (ticker MORN) advanced 0.96 % over the preceding 24‑hour period. At the close, a single share of Morningstar was valued at approximately USD 213.79 on the principal exchanges.
Market Overview
- Current Supply: 37.5 million shares
- Market Capitalisation: USD 7.9 billion
- 24‑Hour Trading Volume: USD 40.6 million
Since the close of the previous month, Morningstar’s share price has risen 9.51 %, underscoring a sustained upward trajectory. The 200‑day simple moving average sits at USD 185.51, indicating a robust trend above a key long‑term support level.
The 52‑week high reached USD 222.00 on 28 October 2025, while the 52‑week low fell to USD 141.49 on 25 June 2026. Morningstar’s current price therefore sits roughly 2.7 % above the annual low and 19.5 % below the annual high, suggesting a moderately favourable valuation corridor for investors.
Comparative Peer Performance (Last 24 Hours)
| Ticker | Last 24‑Hour Change | Current Price (USD) | Market Cap (USD bn) | P/E Ratio |
|---|---|---|---|---|
| ZION (Zions Bank) | 0 % | 65.71 | 9.4 | 8.24 |
| AYI (Acuity) | +1.85 % | 316.76 | 9.5 | 18.17 |
| DAR (Darling Ingredients) | –0.22 % | 59.09 | 9.3 | 16 |
| ORI (Old Republic) | +1.13 % | 40.13 | 9.5 | 8.71 |
| FCFS (Firstcash) | +0.92 % | 216.75 | 9.4 | 24.39 |
Morningstar’s performance aligns with a broader market trend that has favored value‑oriented stocks such as ZION and ORI, while growth‑oriented peers like AYI and FCFS have delivered modest gains. Darling Ingredients, despite a slight dip, remains a stable performer within its sector.
Spotlight on Darling Ingredients
Darling Ingredients recently announced the launch of Nextida NxCogni, a non‑stimulant collagen peptide designed to support cognitive clarity and resilience. Developed on the company’s Nextida platform, the ingredient contains a concentrated blend of neurosupportive peptides and is intended for use in dietary supplements. The firm plans an initial open‑label human study in late 2026, followed by two large randomized controlled trials in early 2027 to validate its pre‑clinical findings. Nextida NxCogni will be showcased at SupplySide Global in Las Vegas, where manufacturers will gain access to samples and detailed information.
Strategic Outlook for Morningstar
Morningstar’s core competency lies in providing high‑quality investment data and analytics to a broad spectrum of investors, from retail individuals to large institutional clients. The company’s diversified product mix—including print, software, and digital platforms—positions it well to capture growing demand for sophisticated market insights.
The firm’s consistent performance, coupled with a solid market cap and favorable 200‑day moving average, suggests that Morningstar remains a compelling option for investors seeking exposure to the financial services sector. Continued emphasis on data integrity and technological innovation is expected to sustain its competitive advantage in the coming years.
